Drugs / GSK2904545A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04026009 | Aug 2019 → May 2022 | Clostridium infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2904545A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04026009 ↗ |
| Modality | Protein / enzyme biologic | “containing a protein (F2 antigen)” PMID 39447053 ↗ Mar 2025 |
| Route | Intramuscular | “The vaccine will be administered intramuscularly in the deltoid” NCT04026009 ↗ |